Biocon Limited   Report issue

For profit Phase 1 Phase 3
Founded: Bangalore India (1978)
Status: No NME R&D (1978)

Organization Overview

First Clinical Trial
2010
NCT01035801
First Marketed Drug
2006
simvastatin (zocor)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Bicara Therapeutics | Biocon Biologics UK Ltd | Biocon Limited | BIOCON LIMITED | BIOCON LTD | BIOCON PHARMA | BIOCON PHARMA LTD | Biocon Research Limited

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Asthma (Phase 1)

Carcinoma (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 1)

Carcinoma, Squamous Cell (Phase 1)

Chordoma (Phase 1)

Coronavirus Infections (Phase 3)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 1 (Phase 1)

Diabetes Mellitus, Type 2 (Phase 3)

Glioblastoma (Phase 1)

Graft vs Host Disease (Phase 2)

Lung Neoplasms (Phase 1)

Lupus Erythematosus, Systemic (Phase 1)

Lupus Nephritis (Phase 1)

Nephritis (Phase 1)

Pancreatic Neoplasms (Phase 1)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Syndrome (Phase 2)

Thyroid Carcinoma, Anaplastic (Phase 1)

Triple Negative Breast Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 10